Exelixis | EXEL - النقدية وما يعادلها





النقدية وما يعادلها تغيير تاريخ
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
Agios Pharmaceuticals USD 113.6M 24.47M 2026-03
Akebia Therapeutics USD 184.84M 18.4M 2025-12
Amgen USD 12.04B 2.91B 2026-03
AstraZeneca USD 7.56B 1.85B 2026-03
Bayer EUR 5.9B 1.34B 2025-09
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Cytokinetics USD 129.84M 7.32M 2026-03
Eisai JPY 301.65B 16.27B 2025-09
Eli Lilly USD 5.28B 1.99B 2026-03
Esperion Therapeutics USD 92.45M 6.39M 2025-09
Exelixis USD 482.49M 106.19M 2025-12
Genmab DKK 1.72B 46M 2025-12
Glaxosmithkline GBP 3.3B 303M 2025-09
Incyte USD 4.02B 435.22M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
MacroGenics USD 57.22M 22.91M 2025-12
Merck USD 5.33B 9.24B 2026-03
Moderna USD 1.91B 687M 2026-03
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Novartis USD 6.88B 4.56B 2026-03
Pfizer USD 1.7B 561M 2026-03
Puma Biotechnology USD 53.52M 1.14M 2025-09
Sanofi EUR 7.66B 1.25B 2025-12
Takeda JPY 654.94B 26.55B 2025-12
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Xencor USD 54.07M 25.78M 2025-12